|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/24/22 Quantrx Biomedical Corp. 8-K:5 8/22/22 10:184K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 8-K Current Report HTML 32K
5: R1 Cover HTML 40K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- form8-k_htm XML 14K
7: EXCEL IDEA Workbook of Financial Reports XLSX 8K
3: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 96K
Document -- qtxb-20220822_lab
4: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 64K
Linkbase Document -- qtxb-20220822_pre
2: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 13K
qtxb-20220822
9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K
10: ZIP XBRL Zipped Folder -- 0001493152-22-023889-xbrl Zip 14K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): i August 22, 2022
Commission File Number i 000-17119
i QUANTRX BIOMEDICAL CORPORATION
(Exact name of registrant as specified in its charter.)
| i Nevada | i 33-0202574 | |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
i 10190 SW 90th Avenue, i Tualatin, i Oregon i 97123
(Address of principal executive offices)
(Registrant’s Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
C:
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective August 22, 2022, Michael Abrams resigned from his position as a member of the Board of Directors of QuantRx Biomedical Corporation (the “Company”). Mr. Abram’s resignation from the Board of Directors is not due to any disagreement with respect to the Company’s operations, policies, or practices.
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
QuantrRx Biomedical Corporation | ||
| August 23, 2022 | By: | /s/ Shalom Hirshman |
| Shalom Hirschman | ||
| Chief Executive Officer | ||
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 8/24/22 | |||
| Filed on: | 8/23/22 | |||
| For Period end: | 8/22/22 | 10-Q | ||
| List all Filings | ||||